Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- platelet aggregation activity
研究概览
简要总结
A natural form of vitamin E called tocotrienol (TCT) has blood thinning and cholesterol lowering properties, both of which may benefit stroke survivors. This study is being conducted to determine the blood thinning and cholesterol lowering properties of TCT in stroke or TIA (transient ischemic attack, which is also referred to as a "mini-stroke") survivors that are receiving the standard treatment for prevention of recurrent stroke.
Study Hypothesis: Oral TCT decreases the incidence of aspirin and clopidogrel nonresponders, increases the extent of inhibition of platelet aggregation, and decreases LDL without significant side effects in stroke patients.
详细描述
In this Phase IIB trial the goal is to determine the effects of orally supplemented TCT on platelet function and cholesterol as well as the safety in patients with TIA (transient ischemic attack) or stroke in addition to the standard treatment for stroke prevention. Recurrent cardiovascular events including stroke, TIA, heart attack, venous thrombosis, pulmonary embolism, systemic embolism will also be recorded. In patients with recurrent stroke, severity of the stroke and stroke size measured from MR (magnetic resonance) or CT (computed tomography) imaging will also be collected. We expect that TCT will inhibit blood clotting and lower cholesterol more than current standard treatment without significantly increasing bleeding risks or other side effects. Future work is planned in a larger TIA/stroke population to examine whether TCT adds to standard medical care in terms of decreasing incidence of stroke and improving outcomes following stroke.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with either atherothrombotic, cardioembolic, cryptogenic stroke or TIA (transient ischemic attack) for whom anticoagulation is not indicated
- •Enrollment in trial must occur within 6 months of clinical presentation for first stroke or TIA event
- •No history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation at least 6mos; within the past 5 years)
- •No current vitamin E supplementation in multi-vitamin
排除标准
- •Disabling stroke ( Modified Rankin Scale > 3)
- •Prior intracranial hemorrhage (excluding traumatic)
- •High risk of bleeding (recurrent gastrointestinal, genitourinary bleeding, active peptic ulcer disease)
- •Anticipated requirement for long term use of anticoagulation
- •Contraindications to antiplatelet agents (bleeding disorder, thrombocytopenia, prolonged INR)
- •Irreversible medical condition likely to affect short-term survival or ability to participate in study such as cancer or other chronic disease with predicted survival of less than a year or severe psychiatric or neurologic disease that might complicate evaluation of study outcomes like dementia or schizophrenia
- •Pregnancy or women of child bearing age who are not following an effective method of contraception
- •Breast feeding
- •Unable or unwilling to provide informed
- •Unlikely to be compliant with therapy or unwilling to return for follow up frequent clinic visits
- •Concurrent participation in another study with an investigational drug or devise
- •Other likely specific cause of stroke such as dissection, infectious or noninfectious vasculitis, prothrombotic state
结局指标
主要结局
platelet aggregation activity
时间窗: up to 1 year
Platelet aggregation activity will be measured using standard clinical laboratory procedures
次要结局
- Incidence of recurrent stroke(up to 1 year)
研究者
Andrew Slivka
MD, Professor of Neurology
Ohio State University